It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

Spruce Biosciences has put out new shoots, snapping up rights to a former BioMarin rare disease candidate and outlining plans ...

The South San Francisco biotech has acquired rights to tralesinidase alfa, an enzyme replacement therapy (ERT) for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BioMarin Pharmaceutical Inc. has advancements in phenylketonuria treatment. Click to learn how Palynziq's success could expand BMRN's market in 2025.

StockNews.com lowered shares of BioMarin Pharmaceutical (NASDAQ:BMRN – Free Report) from a strong-buy rating to a buy rating in a report issued on Tuesday. Other analysts also recently issued research ...

Palynziq significantly lowered blood Phe levels in adolescents vs. diet alone. BioMarin will submit data for label expansion to health authorities this year. The ‘Trade of the Day’ is now live. Get a ...

Wall Street expects a year-over-year increase in earnings on higher revenues when BioMarin Pharmaceutical (BMRN) reports results for the quarter ended March 2025. While this widely-known consensus ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) released topline data from the Phase 3 PEGASUS trial evaluating Palynziq (pegvaliase-pqpz) compared to diet alone in 55 adolescents aged 12-17 with ...